Position in TERN
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$14,332,301
New position
Shares Held
271,857
first reported quarter
Ownership
0.235%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026GABELLI FUNDS LLC holds $96,689,277 across 29 Biotechnology names. TERN ranks #2 (14.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
195,900 | $22,493,238 | |
| 2 | TERN |
Terns Pharmaceuticals, Inc.
This page
|
271,857 | $14,332,301 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
|
942,650 | $13,630,719 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
321,200 | $12,921,876 | |
| 5 | DAWN |
Day One Biopharmaceuticals, Inc.
|
464,097 | $9,950,239 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
65,300 | $4,849,178 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,920 | $3,536,596 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
46,200 | $2,985,906 |
All Filings in TERN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,332,301 | 271,857 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||